Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs) predicted to see the highest increases ...

In a population of middle-aged and older men with hypogonadism, "the incidences of high-grade or any prostate cancer and other prostate events were low and did not differ significantly between ...

Please provide your email address to receive an email when new articles are posted on . Men with an annual 3% increase in CRF had 35% reduced odds of prostate cancer vs. those with decreased CRF. The ...

A new three-phase screening protocol that incorporates a PSA test, a four-kallikrein panel, and an MRI scan appears to improve the prostate cancer detection rate among men invited to participate in a ...

In a recent study published in the journal Prostate Cancer and Prostatic Diseases, researchers investigated the potential associations between human papillomavirus (HPV) infections and prostate ...

A Cochrane review finds PSA blood testing can detect more prostate cancers early and may save lives by catching disease ...